Policy & Regulation
MaxCyte doses first patient in MCY-M11 US phase I dose-escalation clinical trial
12 October 2018 -

United States-based MaxCyte has dosed the first patient in its United States phase I dose-escalation clinical trial of chimeric antigen receptor therapeutic candidate, MCY-M11, it was reported yesterday.

The multi-centre, non-randomised, open label, dose-escalation Phase I clinical trial will evaluate the safety and effectiveness of intraperitoneal infusions of MCY-M11 in individuals with platinum-resistant high-grade serous adenocarcinoma of the ovary, primary peritoneum or fallopian tube, or individuals with advanced peritoneal mesothelioma with recurrence after prior chemotherapy. The study is designed to assess the product, a mesothelin targeting CAR, in individuals with relapsed/refractory ovarian cancer and peritoneal mesothelioma.

Chimeric antigen receptor therapeutic candidate uses messenger RNA (mRNA) as the delivery vehicle for a chimeric antigen receptor transfected into freshly isolated peripheral blood mononuclear cells, allowing for rapid manufacture and delivery back to the patient, without the need for a viral component or cell expansion. The platform offers a cell therapy with transient expression, enabling repeat dosing and with the potential to reduce the cost and minimise adverse side-effects seen in viral-based chimeric antigen receptor therapies.